Press Releases Mustang Bio, Inc.

Equities

MBIO

US62818Q2030

Real-time Estimate Cboe BZX Other stock markets 07:44:40 13/05/2024 pm IST			5-day change	1st Jan Change
0.274 ^USD	+5.38%		-16.18%	-81.31%

02/05	Mustang Bio, Inc. announced that it has received $3.3 million in funding	CI
30/04	Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mustang Bio Announces Closing of $4 Million Public Offering	03/05	AQ
Mustang Bio Announces Pricing of $4 Million Public Offering	30/04	AQ
Mustang Bio : Results of Operations and Financial Condition - Form 8-K	29/04	PU
Mustang Bio : Costs Associated with Exit/Disposal - Form 8-K	13/04	PU
Mustang Bio : Corporate Presentation	01/04	PU
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	28/03	AQ
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	12/03	AQ
City of Hope-developed chimeric antigen receptor T cell therapy shows clinical activity in patients with aggressive brain tumors in a Phase 1 trial	08/03	AQ
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma	07/03	AQ
Mustang Bio : Corporate Presentation	02/03	PU
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference	11/01	AQ
Mustang Bio Presents Updated Phase Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology Annual Meeting	12/12	AQ
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting	11/12	AQ
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights	15/11	AQ
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting	02/11	AQ
Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	30/23/30	AQ
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 and MB-108, for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma	27/23/27	AQ
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	26/23/26	AQ
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma	26/23/26	AQ
Mustang Bio : Corporate Presentation	13/23/13	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Mustang Bio, Inc.

Equities

MBIO

US62818Q2030

Press Releases

Filters